Intellia released additional positive data for lonvoguran ziclumeran (lonvo-z), its one-time in vivo gene-editing therapy for hereditary angioedema (HAE), expanding on earlier Phase 3 endpoint success. Coming just weeks after Intellia said it met its primary endpoint, the company reported secondary endpoints with statistical and clinical significance. The updates reinforce momentum behind a single-dose approach in a field defined by chronic prophylaxis and breakthrough attacks. For HAE patients and payers, the operational impact of avoiding repeated dosing is central, and regulators will scrutinize durability, safety, and the consistency of biomarker responses alongside clinical outcomes. As Intellia advances, the market focus will be on long-term follow-up commitments typical for in vivo editing programs, particularly around safety monitoring and sustained C1 inhibitor and kallikrein pathway control.